TNFRSF8 and Hodgkins lymphoma: In addition, a 22-year-old Hodgkin lymphoma patient suffering from COVID-19 was successfully treated with the PD-1 inhibitor pembrolizumab [51], and the cHL was generally treated with CD30 targeting brentuximab vedotin [18].